Literature DB >> 1333276

Subclassification of class I antiarrhythmic drugs: enhanced relevance after CAST.

T J Campbell1.   

Abstract

Class I antiarrhythmic drugs are traditionally divided into three subclasses--Ia, Ib, and Ic--on the grounds of differences in kinetics of interaction with the sodium channel and different effects on the duration of the action potential. The CAST study has highlighted our growing awareness of the proarrhythmic potential of this group of agents, particularly the Class Ic subgroup. Class I drugs can cause arrhythmias either by slowing conduction to critical levels, thus enhancing the possibility of reentrant arrhythmias, or in some cases by prolonging action potential duration, leading to early afterdepolarizations, which probably underlie triggered automaticity. Evidence is presented that the Class Ic compounds may be inherently more proarrhythmic than the Ib compounds, because of their lesser ability to depress ischemic myocardium selectively. Arguments are advanced for the continued use of a slightly modified subclassification of Class I antiarrhythmic drugs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1333276     DOI: 10.1007/bf00055611

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  50 in total

1.  Differential analysis of the frequency-dependent effects of class 1 antiarrhythmic drugs according to periodical ligand binding: implications for antiarrhythmic and proarrhythmic efficacy.

Authors:  J Weirich; H Antoni
Journal:  J Cardiovasc Pharmacol       Date:  1990-06       Impact factor: 3.105

Review 2.  The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis.

Authors:  W M Jackman; K J Friday; J L Anderson; E M Aliot; M Clark; R Lazzara
Journal:  Prog Cardiovasc Dis       Date:  1988 Sep-Oct       Impact factor: 8.194

3.  Use-dependent effects of lidocaine on conduction in canine myocardium: application of the modulated receptor hypothesis in vivo.

Authors:  J Davis; T Matsubara; M M Scheinman; B Katzung; L H Hondeghem
Journal:  Circulation       Date:  1986-07       Impact factor: 29.690

Review 4.  Antiarrhythmic agents: the modulated receptor mechanism of action of sodium and calcium channel-blocking drugs.

Authors:  L M Hondeghem; B G Katzung
Journal:  Annu Rev Pharmacol Toxicol       Date:  1984       Impact factor: 13.820

5.  The effects of antiarrhythmic drugs, stimulation frequency, and potassium-induced resting membrane potential changes on conduction velocity and dV/dtmax in guinea pig myocardium.

Authors:  J W Buchanan; T Saito; L S Gettes
Journal:  Circ Res       Date:  1985-05       Impact factor: 17.367

6.  Kinetics of onset of rate-dependent effects of Class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification.

Authors:  T J Campbell
Journal:  Cardiovasc Res       Date:  1983-06       Impact factor: 10.787

7.  Depression of maximum rate of depolarization of guinea-pig ventricular action potentials by metabolites of encainide.

Authors:  P D Hemsworth; T J Campbell
Journal:  Br J Pharmacol       Date:  1989-06       Impact factor: 8.739

Review 8.  The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology.

Authors: 
Journal:  Circulation       Date:  1991-10       Impact factor: 29.690

9.  International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings. Impact Research Group.

Authors: 
Journal:  J Am Coll Cardiol       Date:  1984-12       Impact factor: 24.094

10.  Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias. A meta-analysis.

Authors:  J Morganroth; J E Goin
Journal:  Circulation       Date:  1991-11       Impact factor: 29.690

View more
  7 in total

Review 1.  Therapeutic drug monitoring: antiarrhythmic drugs.

Authors:  T J Campbell; K M Williams
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

Review 2.  Antiarrhythmic therapy in atrial fibrillation: indications, guidelines, and safety.

Authors:  Armin Barekatain; Mehdi Razavi
Journal:  Tex Heart Inst J       Date:  2012

3.  Kinetics of rate-dependent slowing of intraventricular conduction by the class Ib antiarrhythmic agent tocainide in vivo.

Authors:  H Todt; N Zojer; G Raberger
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

4.  Electrophysiological basis for antiarrhythmic efficacy, positive inotropy and low proarrhythmic potential of (-)-caryachine.

Authors:  M H Wu; M J Su; S S Lee; L T Lin; M L Young
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

Review 5.  Antiarrhythmic agents: drug interactions of clinical significance.

Authors:  T C Trujillo; P E Nolan
Journal:  Drug Saf       Date:  2000-12       Impact factor: 5.606

6.  Considerations and Caveats when Applying Global Sensitivity Analysis Methods to Physiologically Based Pharmacokinetic Models.

Authors:  Dan Liu; Linzhong Li; Amin Rostami-Hodjegan; Frederic Y Bois; Masoud Jamei
Journal:  AAPS J       Date:  2020-07-17       Impact factor: 4.009

7.  Cardiac sodium channel inhibition by lamotrigine: In vitro characterization and clinical implications.

Authors:  Lindsey Ingleby-Talecki; Sven C van Dijkman; Sean P Oosterholt; Oscar Della Pasqua; Christina Winter; Marianne Cunnington; Linda Rebar; Sergio Forero-Schwanhaeuser; Vickas Patel; James A Cooper; Anthony Bahinski; Khuram W Chaudhary
Journal:  Clin Transl Sci       Date:  2022-05-31       Impact factor: 4.438

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.